.svg)
Does the environment around us contributes to development of MS and ALS through interaction with the immune system? We perform epidemiological and immunological studies in collaboration with world-leading experts. By using unique population-based datasets for environmental exposures and case ascertainment, we explore the impact of lifestyle factors, and how differences in immune regulation appear many years before disease development. We have access to clinical data and patient material from a large cohort of patients with ALS and MS and combine in silico and in vitro experiments to characterize regulation of immune responses within the central nervous system against microbes and autoantigens. We are also deeply involved in clinical trials and initiated a national study on the genetic epidemiology of ALS in Norway.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.
JPND/Horizon 2020-funded project including patients with pre-demented Alzheimer’s disease to find biomarkers for small vessel damage in the brain.
Stet clita kasd gubergren, no sea takimata sanctus est Lorem ipsum dolor sit amet. Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. At vero eos et accusam et justo duo dolores et ea rebum. Stet clita kasd gubergren, no sea takimata sanctus est Lorem ipsum dolor sit amet.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.
AcuteHeadache Evaluation Study. (PIEspen Saxhaug Kristoffersen). Funding by Ahus.
Multidisciplinary HeadacheTreatment. (PI Kjersti Grøtta Vetvik). Effect of headache treatment in amultidisciplinary team on headache burden and work participation. A cooperationwith the Norwegian Labour and welfare administration (NAV).
(PI Christofer Lundqvist) –Treatmentwith Eptinezumab in medication overuse headache. Sponsor Lundbeck AS.
PIChristofer Lundqvist). Candesartan for migraine. CandMig III:Kandesartan som forebyggende medisin ved hyppig migrene - Cristin. Fundedby Klinbeforsk.
(PIEspen Saxhaug Kristoffersen). Home-basedbiofeedback as a migraine treatment. Funded by the Norwegian Headache researchcenter (NorHead) and Nordic Brain tech.
www.biocer.no
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.
Read more“Disease mechanisms in multiple sclerosis and other inflammatory diseases of the central nervous system”
Funded by Norwegian South-Eastern Health Authority and Research council of Norway
“Environmental risk factors for amyotrophic lateral sclerosis”.
Funding from ALS Norway, University of Oslo, Akershus University Hospital
“Mesenchymnal stem cells in amyotrophic lateral sclerosis”.
Funding from Norwegian Research Council and Norwegian South-Eastern healthg Authority
“To B or not to B: Defining pathogenic B cells in multiple sclerosis”
Funding by Norwegian South-Eastern health Authority
“T follicular helper cells as disease-drivers in multiple sclerosis”
Funding by Norwegian South-Eastern health Authority
RAM-MS - RCT on hematopoetic stem cells in MS – Sponsor Helse Bergen.
SMART MS - RCT on mesenchymal stem cells in MS - Sponsor Helse Bergen
OVERLOR-MS - RCT on B cell depletion therapy in MS – Sponsor Helse Bergen.
NO-ALS and NO-ALS extension study – Sponsor Helse Bergen
Premorbidlipid levels and long-term risk of ALS - a population-based cohort study.
Vaage A, Holmøy T, Stigum H, Meyer HE,Nakken O. Amyotrophl Lat Scler 2023, in press.
Tuberculin responses after BCGvaccination predict amyotrophic lateral sclerosis risk.
Nakken O, Vaage AM, StigumH, Heldal E, Meyer HE, Holmøy T. BrainBehav Immun Health. 2023. PMID: 38033614
Nakken O, Holmøy T, Stigum H, Myhr KM, Dahl J,Heldal E, Meyer HE. Int J Epidemiol. 2022. PMID: 35278068
Høglund RAA, Meyer HE, Stigum H, Torkildsen Ø,Grytten N, Holmøy T, NakkenO. Neurology. 2021. PMID:34697245
High BMI is associated withlow ALS risk: A population-based study.
Nakken O, Meyer HE, StigumH, Holmøy T. Neurology. 2019. PMID 31243073
Stereotyped B-cell responsesare linked to IgG constant region polymorphisms in multiple sclerosis.
Lindeman I, Polak J, QiaoSW, Holmøy T, Høglund RA,Vartdal F, Berg-Hansen P, Sollid LM, Lossius A. Eur J Immunol. 2022. PMID35094395
CD4+ T Cellsin the Blood of MS Patients Respond to Predicted Epitopes From B cell ReceptorsFound in Spinal Fluid.
Høglund RA, Bremel RD, Homan EJ, TorsetnesSB, Lossius A, Holmøy T. PMID 32328067
Selective intrathecalenrichment of G1m1-positive B cells in multiple sclerosis.
Lossius A, Tomescu-BaciuA, Holmøy T, Vedeler CA,Røsjø E, Lorentzen ÅR, Casetta I, Vartdal F. Ann Clin Transl Neurol. 2017 PMID 29046884
Ahus EpiGen Labs: Investigation of human immune cells have been depended heavily on the EpiGen facilities at Ahus, allowing patient material to be collected in close proximity to in- and outpatient clinics, and immediately be processed, prepared and analysed. EpiGen offers cell-laboratories, flow cytometers and facilities for advanced molecular biology, as well as biobank facilities.
Regional core facilities: Methods extending beyond the capabilities of the local labs have been outsourced to regional core facilities of localized in Oslo University hospital and University of Oslo
MS biobank: As part of the project “Disease mechanisms in multiple sclerosis and other inflammatory diseases of the central nervous system”, we have collected a comprehensive biobank of cells and spinal fluid from patients with relevant diseases. The biobank is currently located at, and is organized in collaboration with Andreas Lossius, ass. Prof. at University of Oslo.
Health registries: The work on epidemiology is performed in collaboration with national, administrative/compulsory registries like including Norwegian Patient registry, Cause of Death Registry, Norwegian prescription database.
Research outpatient clinic: Ahus provides an in-house research outpatient clinic, that is utilized in our clinical trials to facilitate quick and easy inclusion and follow-up of our patients.
The head Trygve Holmøy is fagansvarlig for “MS rapporten”, an annual report by the Norwegian MS association. We continuously work to improve the standard of care for MS and ALS patients locally and nationally, often in collaboration with the MS association or other regional hospitals.
